NEW YORK (GenomeWeb) – Annai Systems said today that the Glioma Longitudinal Analysis (GLASS) consortium has selected the Secondary and Tertiary Analysis Reporting Platform (STARPlatform), Annai's next-generation sequencing data management solution, to handle whole exome and genome sequence data collected by researchers in participating centers.
The GLASS consortium is led by researchers from the University of Texas MD Anderson Cancer Center, University of California, San Francisco, and the Samsung Medical Center and consists of neuropathologists, clinicians, scientists, and bioinformaticians from multiple institutions. As part of the project, they plan to generate a longitudinal genomics dataset that will represent a cohort of patients across three specified diffuse glioma genomic subtypes, namely IDH-wild-type, IDH-mutant, and IDH-mutant 1p/19q co-deletion.
Consortium researchers aim to understand how these gliomas develop and evolve as well as identify more effective therapies for patients. The STARPlatform "provides a secure, collaborative workspace to normalize and share data, which is exceptionally important to us," Roel Verhaak, the consortium's lead investigator and assistant professor of bioinformatics and computational biology at the MD Anderson Cancer Center, said in a statement.
"We developed our solutions to address the full range of needs for next-generation genomics research, from the individual researcher to large-scale consortia," Annai CEO Michael Penley, noted in a statement. "We're honored to partner with GLASS and provide our services to help them lead the charge in glioma tumor research."
Financial and other terms of the agreement were not disclosed.